Candidate screen of neuropeptide/receptor genes affecting cholinergic transmission at the NMJ. by Jiajie Shao (1729147)

“…All data are presented as mean ± SEM. Statistical significance for multiple-group datasets comparison was determined using one-way ANOVA with Tukey correction. *, **, ***, and **** indicate <i>p</i> < 0.05, <i>p</i> < 0.01, <i>p</i> < 0.001, and <i>p</i> < 0.0001, respectively. …”

Expression analysis of <i>slc13a5</i> zebrafish paralogs (<i>5a</i> and <i>5b</i>) and generation of zebrafish <i>slc13a5</i> mutants using CRISPR/Cas9 technique. by Deepika Dogra (21072023)

Mice brain tissues stained with H&E dye kits (200×). by Wei Zhang (405)

Subjects:

Pearson correlation chart. by Wei Zhang (405)

Subjects:

1,3-DPG contents and PEPC activities in <i>P</i>. <i>ginseng</i>. by Wei Zhang (405)

Subjects:

O2·- and H₂O₂ contents in <i>P</i>. <i>ginseng</i>. by Wei Zhang (405)

Subjects:

NOX activities in <i>P</i>. <i>ginseng</i>. by Wei Zhang (405)

Subjects:

AsA, GSH, GSSH contents, ratio of GSH/GSSH and APX, GR activities in <i>P</i>. <i>ginseng</i>. by Wei Zhang (405)

Subjects:

Content of monomer ginsenosides in <i>P</i>. <i>ginseng</i>. by Wei Zhang (405)

Subjects:

Activities of HMGCR, FPS, SS, SE and DS in <i>P</i>. <i>ginseng</i>. by Wei Zhang (405)

Subjects:

ROS promote ginsenoside biosynthesis under water stress. by Wei Zhang (405)

Subjects:

SOD, CAT and POD activities in <i>P</i>. <i>ginseng</i>. by Wei Zhang (405)

Subjects:

Results of Morris water maze experiment in mice. by Wei Zhang (405)

Subjects:

S1 Data - by Wei Zhang (405)

Subjects:

MDA contents in <i>P</i>. <i>ginseng</i>. by Wei Zhang (405)

Subjects:

GSH-PX, SOD activities and MDA contents in mice brain tissues. by Wei Zhang (405)

Subjects:

PCA of <i>P</i>. <i>ginseng</i>. by Wei Zhang (405)

Subjects:

Contents of total ginsenosides in <i>P</i>. <i>ginseng</i>. by Wei Zhang (405)

Subjects:

Quality and certainty of evidence grades. by Saurabh P. Mehta (20234521)

“…This systematic review will provide crucial information to determine whether an episode of COVID-19 is associated with an increased risk of frailty. The results of this review will have significant clinical implications in mitigating the risk of frailty after COVID-19.…”

Supplementary file 1_Bridging the gaps between randomized controlled trials and real-world use of thrombopoietin receptor agonists for adult primary immune thrombocytopenia: a syst... by Liping Luo (1885879)

“…TPO-RAs reduced bleeding risks (any: OR = 0.43, significant: OR = 0.40, both p < 0.001). Rescue therapy increased from 12% (short-term) to 32% (>12 months). …”